Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies

Area of Science:

• Oncology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC), particularly in Asian populations.
• Tyrosine kinase inhibitors (TKIs) have transformed NSCLC treatment, but disease progression remains a significant challenge.

Purpose of the Study:

• To review current strategies for improving prognosis in patients with EGFR-mutated NSCLC.
• To address the unmet need for enhanced first-line and effective second-line therapies.

Main Methods:

• Literature review of therapeutic strategies for EGFR-mutated NSCLC.
• Analysis of treatment advancements and unmet needs in NSCLC management.

Main Results:

• Osimertinib, a third-generation TKI, shows efficacy but is followed by disease progression in most patients.
• Identification of novel therapeutic avenues to enhance existing treatments and establish robust second-line options.

Conclusions:

• Improving the prognosis of EGFR-mutated NSCLC requires innovative approaches beyond current TKIs.
• Further research into combination therapies and novel agents is crucial to overcome treatment resistance and prolong survival.